Patents by Inventor Rika Kurino

Rika Kurino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibody capable of binding to specific discontinuous epitope occurring in AD1 region of human cytomegalovirus GB glycoprotein, and antigen-binding fragment thereof
    Patent number: 8492529
    Abstract: The present invention provides a pharmaceutical composition for human cytomegalovirus HCMV causative of various disease states, the composition comprising a monoclonal antibody and an antigen-binding fragment thereof that specifically binds to the AD1 region of glycoprotein gB and that has excellent neutralizing capacity. The present invention provides: a monoclonal antibody and an antigen-binding fragment thereof having an excellent neutralizing capacity and cell-to-cell infection blocking capacity and specifically binding to a discontinuous sequence occurring in the HCMV AD1 region; a pharmaceutical composition comprising the antibody or the fragment thereof; and the like.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: July 23, 2013
    Assignee: Evec Incorporated
    Inventors: Kenzo Takada, Rika Kurino, Takashi Torashima
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO SPECIFIC DISCONTINUOUS EPITOPE OCCURRING IN AD1 REGION OF HUMAN CYTOMEGALOVIRUS GB GLYCOPROTEIN, AND ANTIGEN-BINDING FRAGMENT THEREOF
    Publication number: 20120093810
    Abstract: The present invention provides a pharmaceutical composition for human cytomegalovirus HCMV causative of various disease states, the composition comprising a monoclonal antibody and an antigen-binding fragment thereof that specifically binds to the AD1 region of glycoprotein gB and that has excellent neutralizing capacity. The present invention provides: a monoclonal antibody and an antigen-binding fragment thereof having an excellent neutralizing capacity and cell-to-cell infection blocking capacity and specifically binding to a discontinuous sequence occurring in the HCMV AD1 region; a pharmaceutical composition comprising the antibody or the fragment thereof; and the like.
    Type: Application
    Filed: April 1, 2010
    Publication date: April 19, 2012
    Applicant: EVEC INCORPORATED
    Inventors: Kenzo Takada, Rika Kurino, Takashi Torashima